Document is current
Any future updates will be listed below
-
Authors
Cobos, Francisco Avila
Panah, Mohammad Javad Najaf
Epps, Jessica
Long, Xiaochen
Man, Tsz-Kwong
Chiu, Hua-Sheng
Chomsky, Elad
Kiner, Evgeny
Krueger, Michael J.
di Bernardo, Diego
Voloch, Luis
Molenaar, Jan
van Hooff, Sander R.
Westermann, Frank
Jansky, Selina
Redell, Michele L.
Mestdagh, Pieter
Sumazin, Pavel http://orcid.org/0000-0002-1215-4977
-
Funding
Funding for this research was provided by:
H2020 European Research Council (826121)
Division of Cancer Prevention, National Cancer Institute (R21CA223140)
Cancer Prevention and Research Institute of Texas (RP180674)
- License Information
-
More Information
Article History
Received: 11 January 2023
Accepted: 17 July 2023
First Online: 1 August 2023
Declarations
:
: The neuroblastoma and AML studies were approved by the institutional review boards at each institution, including Ghent University and Princess Maxima Center for Pediatric Oncology (neuroblastoma), and Texas Children’s Hospital Cancer Center (AML). All subjects included in this study provided written informed consent for the use of phenotype and molecular data for research. The research conforms to the principles of the Declaration of Helsinki.
: Not applicable.
: L.V. is a shareholder of Immunai. All financial interests are unrelated to this work. The other authors declare no competing interests.
